Center for Retina and Macular Disease

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Macular degeneration9 trials
• Diabetic eye disease7 trials

Phase

• Phase 26 trials
• Phase 36 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Completed6 trials
• Active, not recruiting5 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Boehringer Ingelheim3 trials
• Kodiak Sciences Inc2 trials
• Regeneron Pharmaceuticals2 trials
• Alcon Research1 trial
• Apellis Pharmaceuticals, Inc.1 trial
• and 5 more

Running trials

• Recruiting

  A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

  NCT06962839· Phase 2· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

  NCT06769048· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

  NCT06556368· Phase 3· Kodiak Sciences Inc· Source

• Active, not recruiting

  A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

  NCT06491914· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

  NCT06321302· Phase 2· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT05769153· Phase 1/2· Alcon Research· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Diabetic eye disease1 recruiting
• Macular degeneration1 recruiting

Closed trials

• Completed

  Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

  NCT07501052· Phase 2· Sam Chun Dang Pharm. Co. Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

  NCT06270836· Phase 3· Kodiak Sciences Inc· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

  NCT05893537· Phase 2· Cognition Therapeutics· Source

• Completed

  A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT04740671· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

  NCT04708145· Phase 4· Greater Houston Retina Research· Source

• Completed

  An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

  NCT04770545· Phase 3· Apellis Pharmaceuticals, Inc.· Source

• Completed

  A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

  NCT04527107· Phase 2· Oxurion· Source